Clinical activity of enzalutamide versus docetaxel in men with castration‐resistant prostate cancer progressing after abiraterone

The optimal sequencing of the multiple active agents now available for metastatic castration‐resistant prostate cancer (mCRPC) is unclear. Prior reports have suggested diminished responses to sequential lines of androgen receptor (AR)‐targeted therapies, but it is unknown whether subsequent taxane‐based chemotherapy may be more effective than sequential AR‐targeting treatment. We sought to evaluate the clinical activity of enzalutamide versus docetaxel in men with mCRPC who progressed on abiraterone.